# LAI Intelligence Weekly – December 11, 2025

This week marks significant progress in the long-acting injectable space with Teva's NDA submission for once-monthly olanzapine, while DelSiTech undergoes leadership transition amid expansion. MedinCell reports H1 financials as its partnership portfolio advances.

## TL;DR

- Teva submits NDA to FDA for TEV-'749/mdc-TJK, a once-monthly olanzapine LAI for schizophrenia developed with MedinCell
- DelSiTech announces CEO departure with Martti Hedman appointed as Interim CEO while actively recruiting for Process Engineer and Quality Director roles
- MedinCell publishes H1 FY2025 consolidated financial results covering April-September 2025 period

---

## Top Signals – LAI Ecosystem

Key developments from LAI technology leaders highlight regulatory progress, organizational changes, and financial reporting.

**Medincell's Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults**  
Teva Pharmaceuticals has submitted an NDA to the U.S. FDA for TEV-'749/mdc-TJK, an olanzapine extended-release injectable suspension developed in partnership with MedinCell. The once-monthly treatment targets schizophrenia in adults, representing a significant regulatory milestone for MedinCell's LAI technology platform.  
[Read more](https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf)

**DelSiTech announces a leadership change. Carl-Åke Carlsson, CEO of DelSiTech, leaves the company and the Board nominates Martti Hedman as Interim CEO.**  
DelSiTech has announced the departure of CEO Carl-Åke Carlsson, with the Board appointing Martti Hedman as Interim CEO. This leadership transition comes as the company continues its operations in the LAI technology sector.  
[Read more](https://www.delsitech.com/delsitech-announces-a-leadership-change-carl-ake-carlsson-ceo-of-delsitech-leaves-the-company-and-the-board-nominates-martti-hedman-as-interim-ceo/)

**DelSiTech is Hiring a Process Engineer**  
DelSiTech is actively recruiting for a Process Engineer position, signaling continued operational expansion despite recent leadership changes.  
[Read more](https://www.delsitech.com/delsitech-is-hiring-a-process-engineer/)

**DelSiTech Seeks an Experienced Quality Director**  
DelSiTech has opened recruitment for an experienced Quality Director role, further strengthening its organizational capabilities and quality infrastructure.  
[Read more](https://www.delsitech.com/delsitech-seeks-an-experienced-quality-director/)

**Medincell Publishes its Consolidated Half-Year Financial Results (April 1st, 2025 – September 30, 2025)**  
MedinCell has released its consolidated half-year financial results covering the period from April 1 to September 30, 2025. The report provides stakeholders with financial performance metrics as the company advances its LAI technology partnerships.  
[Read more](https://www.medincell.com/wp-content/uploads/2025/12/MDC_HY-Results-EN_09122025-1.pdf)

---

*Newsletter générée par Vectora Inbox – Powered by Amazon Bedrock*
